国产注射用比伐卢定对大鼠血栓模型血小板活化功能的影响被引量：1

Effect of domestic bivalirudin on platelet activation function in rat model of thrombus

下载PDF

导出

摘要目的探讨国产注射用比伐卢定（domesticbivalimdin）对大鼠颈总动脉血栓模型血小板活化功能的影响。方法建立大鼠左颈总动脉血栓模型，分为对照组（n=6）、模型组（n=10）、国产注射用比伐卢定联合尿激酶（urokinase，UK）组（B＆UK组，n=10）、肝素（heparin）联合尿激酶组（H＆UK组，n=10），检测各组治疗前后GMP-140含量及血栓重量。结果与模型组比较，B＆UK组及H＆UK组血栓重量均明显减轻，而B＆UK组与H＆UK组之间血栓重量比较差异无统计学意义。模型组、B＆UK组及H＆UK组GMP-140含量均显著高于对照组；而治疗后GMP-140含量在B＆UK组显著低于模型组，相反治疗后GMP-140含量在H＆UK组则显著高于模型组。结论国产注射用比伐卢定能在模型中有效抑制血栓形成，但相比肝素，国产注射用比伐卢定能显著抑制血小板活化功能，抑制血小板聚集。在抑制血栓形成过程中国产注射用比伐卢定对血小板活化的影响具有更多优势。 Objectives To explore the effect of domestic bivalirudin on platelet activation function in rat model of carotid artery thrombosis. Methods A rat model of common carotid artery thrombosis was established. The rats were then randomized to control group （n = 6）, model group （n = 10）, domestic bivalirudin plus uroki- nase group （B＆UK, n = 10）, and heparin plus urokinase group （H＆UK, n = 10）. GMP-140 content and thrombus weight were detected before and after treatment. Results As compared with the model group, throm- bus weight was obviously reduced in B＆UK group and H＆UK group. There was no significant difference in thrombus weight between B＆UK group and H＆UK group. GMP-140 content was remarkably greater in the model group, H＆UK group, and B＆UK gourp than in the control group. After treatment, GMP-140 content was signif- icantly increased in H＆UK gourp but obviously reduced in B＆UK gourp. Conclusions Domestic bivalirudin can effectively inhibit formation of thrombosis in the rat model. As compared to heparin, domestic bivalirudin inhibits platelet activation function and platelet aggregation. During inhibition of thrombus formation, domestic bivalirudin has more effects on platelet activation function.

作者陈伟宏吴苏武张淇钏向定成

机构地区汕头市中心医院重症医学科广州军区广州总医院心内科

出处《国际医药卫生导报》 2013年第1期21-24,共4页 International Medicine and Health Guidance News

关键词比伐卢定肝素颈动脉血栓形成大鼠血小板活化 Bivalirudin Heparin Carotid arterial thrombosis Rat Platelet activation function

分类号 R-332 [医药卫生] R9 [医药卫生—药学]

引文网络
相关文献

参考文献11

1White H, Hirulog and Early Reperfiasion or Occlusion(HERO)-2 Trial Investigators.Thrombin-specific anticoagu—lation with bivalirudin versus heparin in patients receivingfibrinolytic therapy for acute myocardial infarction: theHERO-2 randomised trial [J].Lancet,2001,358 (9296):1855-1863.
2Anand SX,Kim MC,Kamran M,et al. Comparison of plateletfunction and morphology in patients undergoing percutaneouscoronary intervention receiving bivalirudin versus unfrac-tionated heparin versus clopidogrel pretreatment and hi-valirudin[J]. Am J Cardiol,2007,100(3):417-424.
3Pratic 6 D,Pasin M,Barry OP,et al.Iron-dependent humanplatelet activation and hydroxyl radical formation : involve-ment of protein kinase C [J].Circulation, 1999,99 (22):3118-3124.
4Kurz KD, Main BW,Sandusky GE. Rat model of arterialthrombosis induced by ferric chloride [JJ.Thromb Res,1990,60(4):269-280.
5Toka M, Ozeren A, Aktan M,et al.The role of inflammationmarkers in triggering acute conr-onary events [J]. HeartVessels,2003,18(4) :171-176.
6Anrlr e P,Hartwell D,Hrachovinov a I,et al. Pro—coagulantstate resulting from high levels of soluble P-selectin in blood[J], Proc Natl Acad Sci USA,2000,97(25): 13835-13840.
7雷朝晖,刘建伟.低分子肝素对下肢深静脉血栓的应用[J].国际医药卫生导报,2003,9(16):10-11. 被引量：3
8Vance GN, Brad L, William QC,et al. Argatrohan, Bi-valirudin, and Lepimdin do not Decrease Clot Propagationand Strength as Effectively as Heparin-activated Antithrom-hin In Vitro [J]. The Journal of Hear Lung Transplantation,2006,189(6):653-662.
9Schneider DJ, Keating F,Sobel BE.Greater inhibitory effectsof bivalirudin compared with unfractionated heparin plus ep-tifibitide on thrombin-induced platelet activation[J].CoronaryArtery Disease,2006,17(5) :471-476.
10潘春梅,向定成,朱爱辛,顾晓龙,龚志华,文艳飞.国产注射用比伐卢定和肝素在冠状动脉介入治疗术中对血小板功能的影响[J].中国循环杂志,2009,24(5):329-332. 被引量：14

二级参考文献11

1Aggarwal A, Sobel BE, Schneider DJ, et al. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis, 2002,13 ( 3 ) : 161-165.
2Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol, 2007,100 (3) : 417-424.
3Vance GN, Brad L,William QG,et al. Argatroban, Bivalirudin, and Lepirudin do not Decrease Clot Propagation and Strength as Effectively as Heparin-activated Antithrombin In Vitro. The Journal of Heart and Lung Transplantatian, 2006,189 (6) :653-662.
4Friederike K, Harold LD, Deborah AW, et al. Increased expression of platelet P-selectin and formation of platelet--leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thrombosis Research, 2006,118 ( 7 ) , 361-369.
5Eli IL, Rajnikant P, Azim K, et al. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients. Thromb Haemost,2006,95(7) : 441-446.
6David JS, Friederike K, Burton ES, et al. Greater inhibitory effects of bivalinldin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation. Coronary Artery Disease, 2006, 121 (7) :471-476.
7Andrew J, Leger BA, Suzanne L, et al Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis. Circulation ,2006,113 ( 1 ) : 1244-1254.
8John AB, John ST, Jeffrey BR. Treatment with Bivalirudin ( HIRU- LOG) as Compared with Heparin during Cornary Angioplasty for Unstable or Postinfarction Angina. N Engl J Med, 1995,333 (3):764- 769.
9[1]Cosmi b, Hirsh j. Low Molecular weight heparins. Current Opinion in Cardiology, 1994,9:612-618
10[2]Leizorovicz A, Simonneau G, decousus H, et al. Compairson of afficacy and safety of low molecular weight heparins and unfractionated heparin ininitial treament of deep venous thrombosis:a meta-anaiysis. Br Med j,1994,309:299-304